All In Biotech

Drug Trial Radar · NCT05673057

Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Phase 1/2a, First-in-human, Open-label, Multicenter, Dose Escalation Study of MP0533 in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Dec 29, 2022

Primary completion

May 29, 2026

Study completion Sep 14, 2026

Sponsor

Lead sponsor
Molecular Partners AGIndustry
Sponsor type
Industry
First posted
Jan 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of MP0533 in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

Conditions

  • Leukemia
  • Myeloid
  • Acute
  • Newly Diagnosed

Interventions

  • MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1Drug

    MP0533 is administered by intravenous infusion

  • MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm ADrug

    * MP0533 is administered by intravenous infusion * Obinutuzumab pretreatment administered

  • MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclaxDrug

    * MP0533 is administered by intravenous infusion * Azacitidine is administered by subcutaneous injection for 7 days per cycle * Venetoclax is administered orally for 14 days per cycle * Optional obinutuzumab pretreatment administered

  • MP0533 with Obinutuzumab pretreatmentDrug

    * MP0533 is administered by intravenous infusion at densified dosing schedule * Obinutuzumab pretreatment administered

  • MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AMLDrug

    * MP0533 is administered by intravenous infusion * Azacitidine is administered by subcutaneous injection for 7 days per cycle * Venetoclax is administered orally for 14 days per cycle * Optional obinutuzumab pretreatment administered

  • MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patientsDrug

    * MP0533 is administered by intravenous infusion * Azacitidine is administered by subcutaneous injection for 7 days per cycle * Venetoclax is administered orally for 14 days per cycle * Optional obinutuzumab pretreatment administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 dose escalation: Recommended Phase 2 Dose Regimen and/or Maximum Tolerated Dose RegimenTime frame: from start of treatment to end of first cycle (day 1 - 28)
  2. Phase 2 dose extension: Overall Response RateTime frame: throughout the study (on average 3 months)

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • CHU Bordeaux

    Bordeaux, France

  • AP-HP Hôpital Saint-Louis

    Paris, France

  • IUCT Oncopole

    Toulouse, France

  • Vilnius University Hospital Santaros Klinikos

    Vilnius, Lithuania

  • Amsterdam UMC - Locatie VUmc

    Amsterdam, Netherlands

  • Erasmus MC

    Rotterdam, Netherlands

  • Groningen UMC

    Groningen, Provincie Groningen, Netherlands

  • Inselspital, Universitaetsspital Bern

    Bern, Canton of Bern, Switzerland

  • Universitaetsspital Zuerich

    Zurich, Canton of Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.